Featured News

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

Thank you to Provention Bio, Inc., for supporting our upcoming Patient Education and Advocacy Summit. Provention Bio, Inc., is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Register now to be a part of this monumental event!

The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).

PROACTIVE Celiac Study is a phase 2 clinical trial testing the investigational medication PRV-015. In combination with a gluten-free diet, PRV-015 aims to reduce symptoms and intestinal inflammation caused by accidental gluten exposure.

The Celiac Disease Foundation National Patient Advocacy Summit in Washington, DC will train participants to advocate on celiac disease public policy priorities to Members of Congress.